{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:16:55Z","timestamp":1790662615822,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1093\/ndt\/gfs528","type":"journal-article","created":{"date-parts":[[2012,12,8]],"date-time":"2012-12-08T02:40:56Z","timestamp":1354934456000},"page":"953-964","source":"Crossref","is-referenced-by-count":64,"title":["Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study"],"prefix":"10.1093","volume":"28","author":[{"given":"Chaim","family":"Charytan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marializa V.","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelia","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Bregman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,12,5]]},"reference":[{"key":"key\n\t\t\t\t20170518085858_GFS528C1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0272-6386(97)90192-X","article-title":"Iron management in end-stage renal disease","volume":"29","author":"Fishbane","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20170518085858_GFS528C2","first-page":"161","article-title":"Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron","volume":"19","author":"Gotloib","year":"2006","journal-title":"J Nephrol"},{"key":"key\n\t\t\t\t20170518085858_GFS528C3","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1046\/j.1523-1755.1999.055Suppl.69079.x","article-title":"Intravenous iron for the treatment of predialysis anemia","volume":"69","author":"Silverberg","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"key\n\t\t\t\t20170518085858_GFS528C4","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1053\/j.ajkd.2006.03.011","article-title":"Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults","volume":"47","author":"KDOQI; National Kidney Foundation: II","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20170518085858_GFS528C5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/asheducation-2010.1.338","article-title":"Clinical use of intravenous iron: administration, efficacy, and safety","volume":"2010","author":"Auerbach","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"key\n\t\t\t\t20170518085858_GFS528C6","article-title":"Ferrlecit prescribing information"},{"key":"key\n\t\t\t\t20170518085858_GFS528C7","article-title":"Venofer prescribing information"},{"key":"key\n\t\t\t\t20170518085858_GFS528C8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1586\/ehm.11.31","article-title":"Ferumoxytol for the treatment","volume":"4","author":"Rosner","year":"2011","journal-title":"Exp Rev Hematol"},{"key":"key\n\t\t\t\t20170518085858_GFS528C9","first-page":"341","article-title":"Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol","volume":"3","author":"Santosh","year":"2010","journal-title":"Nephrol Dial Transplant Plus"},{"key":"key\n\t\t\t\t20170518085858_GFS528C10","first-page":"219","article-title":"Assessment of dextran antigenicity of intravenous iron products by an immunodiffusion assay","volume":"25","author":"Neiser","year":"2011","journal-title":"Port J Nephrol Hypert"},{"key":"key\n\t\t\t\t20170518085858_GFS528C11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2165\/00003495-200969060-00007","article-title":"Ferric carboxymaltose: a review of its use in iron-deficiency anaemia","volume":"69","author":"Lyseng-Williamson","year":"2009","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20170518085858_GFS528C12","first-page":"345","article-title":"The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose","volume":"60","author":"Funk","year":"2010","journal-title":"Arzneimittelforschung"},{"key":"key\n\t\t\t\t20170518085858_GFS528C13","first-page":"362","article-title":"Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia","volume":"60","author":"Geisser","year":"2010","journal-title":"Arzneimittelforschung"},{"key":"key\n\t\t\t\t20170518085858_GFS528C14","first-page":"373","article-title":"Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder","volume":"60","author":"Geisser","year":"2010","journal-title":"Arzneimittelforschung"},{"key":"key\n\t\t\t\t20170518085858_GFS528C15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2326-11-4","article-title":"Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data","volume":"11","author":"Moore","year":"2011","journal-title":"BMC Blood Disorders"},{"key":"key\n\t\t\t\t20170518085858_GFS528C16","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/j.1572-0241.2007.01744.x","article-title":"A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial","volume":"103","author":"Kulnigg","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170518085858_GFS528C17","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/ndt\/gfq613","article-title":"A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients","volume":"26","author":"Qunibi","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170518085858_GFS528C18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1755-6686.2009.00075.x","article-title":"The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients","volume":"35","author":"Tagboto","year":"2009","journal-title":"J Ren Care"},{"key":"key\n\t\t\t\t20170518085858_GFS528C19","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/j.1537-2995.2009.02327.x","article-title":"Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial","volume":"49","author":"Van Wyck","year":"2009","journal-title":"Transfusion"},{"key":"key\n\t\t\t\t20170518085858_GFS528C20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.AOG.0000275286.03283.18","article-title":"Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial","volume":"110","author":"Van Wyck","year":"2007","journal-title":"Obstet Gynecol"},{"key":"key\n\t\t\t\t20170518085858_GFS528C21","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1053\/j.gastro.2011.06.005","article-title":"FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease","volume":"141","author":"Evstatiev","year":"2011","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170518085858_GFS528C22","article-title":"Revisions to the EPO\/Aranesp Monitoring Policy","author":"Department of Health and Human Services","year":"2006"},{"key":"key\n\t\t\t\t20170518085858_GFS528C23","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1093\/ndt\/gfq260","article-title":"Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds","volume":"25","author":"Toblli","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170518085858_GFS528C24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1055\/s-0031-1296218","article-title":"Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model","volume":"61","author":"Toblli","year":"2011","journal-title":"Arzneimittelforschung"},{"key":"key\n\t\t\t\t20170518085858_GFS528C25","volume-title":"Direct Comparison of Ferric Carboxymaltose vs. Venofer in 2500 Patients with Iron Deficiency Anemia and Impaired Renal function (REPAIR-IDA)","author":"Szczech","year":"2011"},{"key":"key\n\t\t\t\t20170518085858_GFS528C26","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1097\/CCM.0b013e31819cec94","article-title":"Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss","volume":"37","author":"Arroliga","year":"2009","journal-title":"Crit Care Med"},{"key":"key\n\t\t\t\t20170518085858_GFS528C27","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","article-title":"Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia","volume":"45","author":"Shimizu","year":"2009","journal-title":"Bone"},{"key":"key\n\t\t\t\t20170518085858_GFS528C28","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1210\/jc.2008-2396","article-title":"FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study","volume":"94","author":"Schouten","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20170518085858_GFS528C29","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/TP.0b013e3181f00a18","article-title":"Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient","volume":"90","author":"Mani","year":"2010","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20170518085858_GFS528C30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5414\/CNP71125","article-title":"Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients","volume":"71","author":"Grimmelt","year":"2009","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t20170518085858_GFS528C31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1159\/000320733","article-title":"Importance of ferritin for optimizing anemia therapy in chronic kidney disease","volume":"32","author":"Nakanishi","year":"2010","journal-title":"Am J Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/28\/4\/953\/12930673\/gfs528.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T16:54:14Z","timestamp":1562432054000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article-lookup\/doi\/10.1093\/ndt\/gfs528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,5]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,12,5]]},"published-print":{"date-parts":[[2013,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfs528","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717969513.793469588","asserted-by":"object"}]},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12,5]]}}}